CNV may develop in 5%–10% of eyes with an axial length greater than 26.5 mm, with or without lacquer cracks or widespread chorioretinal degeneration (Fig 4-17). Treatment with laser therapy is often complicated when the laser scar expands through the foveal center over time (so-called atrophy creep). Although PDT has been shown to be beneficial, the mainstay of treatment is now intravitreal anti-VEGF therapy due to the excellent visual and anatomical outcomes. Several studies have demonstrated sustained regression of myopic CNV after anti-VEGF treatment, with stabilization or improvement of visual acuity after only 1 or 2 injections. For a more detailed discussion of myopia and pathologic myopia, please see Chapter 10 in this volume.
Excerpted from BCSC 2020-2021 series: Section 10 - Glaucoma. For more information and to purchase the entire series, please visit https://www.aao.org/bcsc.